Applying stem cell technology for cardiovascular indications is not just an idea anymore.

CardioCell is currently in clinical trials using stem cells to develop “off-the-shelf” products for cardiovascular indication. The company is exploring unmet medical needs in:

  • Acute Myocardial Infarction (AMI)
  • Chronic Heart Failure (CHF)
  • Peripheral Artery Disease (PAD)

For clinical trials, CardioCell is using cGMP allogeneic stem cells derived from the bone marrow of healthy volunteers. These cells are manufactured in a licensed cGMP-compliant facility.

CardioCell’s scientific board members and clinical trial principal investigators collaborated on a peer-reviewed paper published in the Journal of Cardiovascular Medicine. For more detail, CLICK HERE.
Clinical Trials Update
Visit CardioCell at ESC Congress 2016 in Rome Aug. 27-31. The first published, preliminary results for CardioCell's Phase IIa heart failure study will be shared at a “Hot Line” Late-Breaking Science Session on Aug. 28 at 12:12 p.m. For more information, CLICK HERE.
Latest News
CardioCell completes enrollment for a Phase IIa clinical trial using its stem cells for participants with chronic heart failure. Preliminary results are anticipated later this year. READ MORE HERE.